Last updated on January 2020

Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: bladder cancer | Urothelial Cancer | Bladder Carcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Histopathologically confirmed non-muscle-invasive transitional cell carcinoma (< pT2)
    Newly diagnosed disease
    Able to be randomized within twelve months of diagnostic transurethral resection
    bladder tumor/biopsy
    Must meet 1 of the following recurrence risk criteria:
    Intermediate risk
    Multiple G1 pTa (> 1)
    Solitary G1 pTa (≥ 3 cm)
    G2 pTa
    G1 pT1
    G2 pT1 (1 or 2 tumors)
    High risk
    G3 pTa
    G3 pT1
    Multiple G2 pT1 (3 or more foci)
    Low risk
    Solitary G1 pTa < 3 cm
    Not pregnant or breast feeding
    No HIV infection
    No condition that, in the opinion of the local investigator, might interfere with the
    afety of the patient or evaluation of the trial objectives
    No concurrent immunosuppressive therapy after organ transplantation
    No concurrent cyclosporine
    Those who currently use or have used selenium and/or vitamin E supplements will not
    be excluded, however, they must agree not to take supplements containing selenium and
    vitamin E above a pre-specified dosage

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.